Related Experiment Videos
alpha-Interferon therapy for HBV-related glomerulonephritis
E P Lopes Neto1, L V Lopes, G M Kirsztajn
1lucia@gastro.epm.br
Sao Paulo Medical Journal = Revista Paulista De Medicina
|February 25, 1999
Summary
Hepatitis B virus (HBV)-related membranous glomerulonephritis (MGN) may improve with interferon-alpha (IFN-alpha) therapy. A patient experienced a temporary flare-up before seroconversion, indicating HBV
Area of Science:
- Nephrology
- Hepatology
- Immunology
Background:
- Membranous glomerulonephritis (MGN) is a common cause of nephrotic syndrome in adults.
- Hepatitis B virus (HBV) infection is an identified cause of secondary MGN.
- The management of HBV-related MGN remains challenging.
Observation:
- A 35-year-old male patient presented with nephrotic syndrome and active HBV infection.
- The patient underwent a 24-week course of interferon-alpha (IFN-alpha) therapy.
- During therapy, transient elevations in aminotransferase and proteinuria were observed.
Findings:
- The observed "flare-up" of liver and kidney disease preceded HBV antigen/antibody seroconversion.
- This flare-up suggests increased in vivo HBV activity.
- The findings support the direct role of HBV in the pathogenesis of MGN.
Implications:
- Interferon-alpha therapy may be a viable treatment option for HBV-related MGN.
- Monitoring for transient disease flares during IFN-alpha therapy is crucial.
- This case highlights the complex interplay between HBV infection and kidney disease.